Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.

about

Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.

Item

http://www.wikidata.org/entity/Q47261672

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.

@en

Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.

@nl

type

Item

label

Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.

@en

Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.

@nl

prefLabel

Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.

@en

Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.

@nl

P1476

Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.

@en

P2093

Ariane Stollenwerk

http://www.w3.org/2001/XMLSchema#string

Christian Elling

http://www.w3.org/2001/XMLSchema#string

Detlef von Zabern

http://www.w3.org/2001/XMLSchema#string

Fabian Heisig

http://www.w3.org/2001/XMLSchema#string

Melanie Sohns

http://www.w3.org/2001/XMLSchema#string

P2860

Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity

Tapentadol Hydrochloride

Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.

The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity.

Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients

Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects.

Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.

Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.

(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.

Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study.

P2888

s12325-017-0654-0

P304

12-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S12325-017-0654-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29270779

http://www.w3.org/2001/XMLSchema#string

P921

phenols

hydrocarbon

P932

5778188

http://www.w3.org/2001/XMLSchema#string